Killexams.com ST0-116 real questions | Pass4sure ST0-116 real questions |

Pass4sure ST0-116 dumps | Killexams.com ST0-116 actual questions | http://heckeronline.de/

ST0-116 Symantec Data Loss Prevention 11(R) Technical Assessment

Study lead Prepared by Killexams.com Symantec Dumps Experts


Killexams.com ST0-116 Dumps and actual Questions

100% actual Questions - Exam Pass Guarantee with tall Marks - Just Memorize the Answers



ST0-116 exam Dumps Source : Symantec Data Loss Prevention 11(R) Technical Assessment

Test Code : ST0-116
Test cognomen : Symantec Data Loss Prevention 11(R) Technical Assessment
Vendor cognomen : Symantec
real questions : 176 actual Questions

can i learn dumps Q & A of ST0-116 examination?
nicely, I did it and that i cant trust it. I could in no pass beget passed the ST0-116 with out your assist. My score changed intoso tall i used to be amazed at my overall performance. Its just because of you. thanks very an dreadful lot!!!


those ST0-116 dumps works in the actual check.
a few rightly men cant carry an alteration to the worlds pass however they are able to best let you know whether you beget got been the only guy who knew a pass to try this and that i requisite to be regarded in this world and design my own notice and i beget been so lame my entire pass but I know now that I wanted to assemble a skip in my ST0-116 and this could design me celebrated perhaps and yes i am brief of glory however passing my A+ exams with killexams.com became my morning and night glory.


Passing ST0-116 exam became my first experience but august enjoy!
I subscribed on killexams.com with the aid of the suggession of my buddy, as a pass to assemble some greater useful resourcefor my ST0-116 checks. As quickly as I logged on to this killexams.com I felt relaxed and relieved on account that I knew this could benefit me assemble thru my ST0-116 test and that it did.


can i learn actual buy a glimpse at questions Q & A present day ST0-116 examination?
To become a ST0-116 Certified, I was in push to pass the ST0-116 exam. I tried and failed last 2 attempts. Accidently, I got the killexams.com material through my cousin. I was very impressed with the actual questions material. I secured 89%. I am so cheerful that I scored above the margin notice without difficulty. The material is nicely formatted as well as enriched with necessary concepts. I contemplate it is the august option for the exam.


Questions had been exactly identical as I got!
It is a captains job to steer the ship just enjoy it is a pilots job to steer the plane. This killexams.com can be called my captain or my pilot because it steered me in to the privilege direction before my ST0-116 test and it was their directions and guidance that got me to result the privilege path that eventually lead me to success. I was very successful in my ST0-116 test and it was a minute of glory for which I will forever remain obliged to this online study center.


Extract coincident total ST0-116 path contents in actual questions layout.
When I had taken the conclusion for going to the exam then I got a august advocate for my preparation from the killexams.com which gave me the realness and reliable exercise ST0-116 prep classes for the same. Here, I besides got the opportunity to assemble myself checked before emotion confident of performing well in the pass of the preparing for ST0-116 and that was a nice thing which made me consummate ready for the exam which I scored well. Thanks to such things from the killexams.


you recognize the fine and fastest manner to pass ST0-116 examination? I got it.
I although that if I may additionally want to clear their ST0-116 check and confident this is as soon as I got here to recognise with my antique top class buddy that killexams.com is the one that would be the boon for me because it were given me my intelligence finally again which I had misplaced for some time and that i desire that this may in no manner assemble over for me getting my ST0-116 check cleared in the end.


Surprised to perceive ST0-116 dumps!
killexams.com gave me an excellent preparation tool. I used it for my ST0-116 exam and got a maximum score. I savor the pass killexams.com does their exam preparation. Basically, this is a dump, so you assemble questions that are used on the actual ST0-116 exams. But the exam simulator and the exercise exam format benefit you memorize it total very well, so you finish up learning things, and will be able to draw upon this lore in the future. Very august quality, and the exam simulator is very light and user friendly. I didnt forward across any issues, so this is excellent value for money.


it's far genuinely first rate experience to beget ST0-116 state-statemodern dumps.
To assemble success in ST0-116 exam. human beings accept as just with that a scholar requisite to possess sharp brain. although it is true but it isnt absolutely actual in view that along with the scholar, the instruct or the trainer ought to besides be rightly certified and educated. I experience blessed that i used to be chummy with this killexams.com in which I met such brilliant educators who taught me how to clear my ST0-116 test and were given me through them with a breeze. I thank them with the bottom of my coronary heart.


Get the ones ST0-116 actual exam questions and answers! finish now not assemble ripplatestf
I might buy a privilege to mention Many Many pass to total team individuals of killexams.com for presenting the sort of tremendous platform made to be had to us. With the benefit of the web questions and caselets, i beget efficaciously cleared my ST0-116 certification with 81% marks. It become truly beneficial to understand the sort and patterns of questions and reasons provided for solutions made my principles crystal smooth. Thank you for total the manual and maintain doing it. total of the trait killexams.


Symantec Symantec Data Loss Prevention

Symantec’s Cloud entry security broker and information Loss Prevention options receive FedRAMP "In system” Designation | killexams.com actual Questions and Pass4sure dumps

Symantec (Nasdaq: SYMC), the realm's main cyber security company, today announced it has acquired an "In technique” designation from the Federal haphazard and Authorization administration application (FedRAMP) for its Cloud entry security broking service (CASB) and data Loss Prevention (DLP) solutions below sponsorship of the department of indigenous land safety (DHS).

Named a pacesetter via traffic analysts, Symantec’s CASB solution allows for agencies to confidently leverage cloud applications and services in a secure, comfy and compliant method. It offers visibility into shadow IT, enforces governance over statistics in cloud applications and gives insurance diagram in opposition t threats focused on cloud bills and functions. Symantec’s DLP solution offers a unique console and unified policy management for every channel – cloud, endpoints, storage, e mail and net – to assist give protection to sensitive facts anywhere it is used throughout these channels.

"Symantec continues to be dedicated to assisting executive agencies give protection to their most constructive asset – their facts,” stated Chris Townsend, vp of federal at Symantec. "We buy into account the exciting challenges their federal shoppers kisser and are making strategic investments to advocate them securely and confidently migrate to the cloud. Getting their items FedRAMP approved indicates their commitment to the executive and positions us a depended on companion and consultant.”

An "In system” designation indicates that a Cloud provider provider (CSP) is actively working on the documentation and controls required to obtain a FedRAMP authorization, and that an company is reviewing that documentation with the intent to deliver an Authority to operate that meets the FedRAMP requirements. CSPs deemed as "In system” are positioned on the FedRAMP market, which highlights cloud provider choices with FedRAMP designations.

CASB and DLP are the latest Symantec choices to trail in the course of the FedRAMP authorization procedure. In February, Symantec’s e mail safety provider – govt bought FedRAMP authorization, and Symantec has a roadmap centered for its different cloud security tools and items to trail in the course of the FedRAMP certification system.

Symantec’s strategy is to assist clients meet the challenges of the cloud generation via its built-in Cyber defense Platform, unifying coverage for both cloud-based mostly purposes and on-premises tools and technologies. This enables a cohesive routine to possibility management, presenting obligatory visibility, context and manage to achieve a far better protection baseline for the executive. Symantec plans to bring this means on AWS GovCloud at the middling baseline.

About Symantec

Symantec organisation (NASDAQ: SYMC), the area's main cyber protection business, helps companies, governments and individuals comfy their most faultfinding records at any locality it lives. agencies the world over glimpse to Symantec for strategic, built-in solutions to preserve in opposition t sophisticated attacks across endpoints, cloud and infrastructure. Likewise, a world community of greater than 50 million americans and households matter on Symantec's Norton and LifeLock product suites to present protection to their digital lives at home and across their devices. Symantec operates one of the world's biggest civilian cyber intelligence networks, enabling it to glimpse and give protection to towards the most superior threats. For more information, gladden visit www.symantec.com or unite with us on facebook, Twitter, and LinkedIn.


Symantec statistics Loss Prevention: Product overview | killexams.com actual Questions and Pass4sure dumps

Symantec presents a complete strategy to information loss prevention that covers both on-premises and cloud environments, in addition to cell devices.

The antivirus supplier's routine to statistics loss prevention (DLP) has advanced rather just a little over the final decade. Symantec bought DLP maker Vontu in 2007, and they integrated the enterprise's know-how into the Symantec protection suite. Symantec's DLP providing later expanded to covered numerous components, together with Symantec DLP for Cloud Storage, Symantec DLP Cloud prevent for Microsoft workplace 365, Symantec information Loss Prevention for Endpoint, Symantec records Loss Prevention for cellular, Symantec records Loss Prevention network and Symantec facts Loss Prevention for Storage.

these days, the product is integrated with the cloud access security broker capabilities of the Symantec CloudSOC. The current version of Symantec data Loss Prevention, 14.6, includes integration with products from Blue Coat techniques, which Symantec obtained in 2016.

Deployment

Symantec statistics Loss Prevention's structure incorporates content-mindful detection servers and endpoint brokers, plus a unified administration platform. The suite is scalable to lots of of thousands of users and gadgets. it may possibly even be deployed on premises, in hybrid cloud environments and as a managed provider through a Symantec managed safety service issuer associate.

Amazon internet capabilities (AWS) lead allows for DLP content material detection servers to be deployed on AWS infrastructure. This enables agencies to monitor and protect elegant facts establish in AWS-hosted circumstances of Microsoft trade and SharePoint.

On the different conclusion of the spectrum, the DLP administration server, content material detection servers and Oracle database can besides be deployed on a unique actual server for little businesses or far off workplaces, thereby decreasing hardware and maintenance charges.

cellular insurance policy

The Symantec facts Loss Prevention suite besides includes monitoring for cellular contraptions and mobile email via Symantec DLP for mobile with cell e-mail monitor and cellular evade. cell email array screen helps Android and iOS contraptions and may notice when employees download elegant corporate records to their mobiles devices the usage of the Microsoft alternate ActiveSync protocol.

commercial enterprise and endpoint insurance plan

normal commercial enterprise architectures are supported with a pair of tools and accessories within the Symantec facts Loss Prevention suite.

For the Symantec facts Loss Prevention for Endpoint product, the Symantec DLP Endpoint find and Symantec Endpoint avoid modules control statistics in use. These modules achieve indigenous scanning, detection and monitoring for macOS, windows 7, windows 8 and windows 10 machines.

On the endpoints, these modules besides computer screen and manage cloud storage sync folders, Outlook and Lotus Notes electronic mail purchasers, HTTP/HTTPS and FTP protocol site visitors, removable storage media -- akin to USB, media transfer protocol, CompactFlash and SD playing cards -- plus eSATA and FireWire for moveable drives. The modules besides video array and manage digital desktops, reminiscent of Citrix, Microsoft Hyper-V and VMware.

statistics in motion is addressed with the aid of Symantec DLP network array screen, community linger away from for e-mail and network evade for net. information at ease is monitored using Symantec DLP network discover, community protect, statistics perception and the statistics perception Self-provider Portal.

Cloud aspects

The suite helps cloud deployments with Symantec DLP for Cloud Storage and Cloud linger away from for Microsoft workplace 365.

Symantec DLP for Cloud Storage is an information-at-leisure device that scans sphere company and commercial enterprise bills. it might probably aid investigate the locality sensitive suggestions is being saved, the pass it's used and who is receiving it. It will besides be configured to assist clients reform policy violations by pass of inserting visible tags on sphere files so clients can remediate policy violations the usage of the Symantec DLP Self-provider Portal.

The Cloud File Sync and share feature maintains users from syncing sensitive statistics data from their computer to cloud file sharing sites corresponding to field, Dropbox, Google power, Hightail, iCloud and Microsoft OneDrive.

Symantec DLP Cloud avoid for Microsoft office 365, meanwhile, monitors and controls emails sent from Microsoft office 365 cases of Microsoft alternate on-line. it works with current Symantec DLP guidelines for change, enabling a company to migrate its change servers to the cloud.

summary

The Symantec facts Loss Prevention suite is designed to meets the wants of tremendous companies, in addition to little and medium-sized companies. The product covers quite a lot of areas, including endpoint statistics in use, network information in transit, and files and databases at rest. Symantec statistics Loss Prevention addresses on-premises, cell and cloud records and can be deployed on both physical servers -- home windows Server, red Hat traffic Linux and others -- and cloud infrastructures, corresponding to AWS. Symantec is at present readying edition 15 of the product, even though a free up date has now not been made public yet.

businesses interested in Symantec facts Loss Prevention may silent contact the dealer or an authorized reseller confederate for pricing and other suggestions.


Symantec to present protection to personal counsel From Leaving the iPad(R) With current records Loss Prevention solution for drugs | killexams.com actual Questions and Pass4sure dumps

BARCELONA, SPAIN--(Marketwire -10/04/11)- Symantec imaginative and prescient 2011 -- Symantec Corp. (NASDAQ: SYMC - news) nowadays announced it is planning to present Symantec statistics Loss Prevention for pill, the first complete records loss prevention (DLP) solution for the monitoring and insurance policy of elegant tips on tablet computer systems. attainable first for the Apple iPad, Symantec information Loss Prevention for tablet will advocate remedy one of the vital pressing problems facing safety groups today by offering content-aware protection for this remarkably accepted current corporate endpoint. The solution is designed to preserve user productiveness and give protection to a firm's private records on the identical time.

examine extra certain blog submit:

in line with Symantec's fresh status of security Survey, businesses are grappling with current security challenges stemming from the proliferation of pills in the business. Of those surveyed, 47 percent pointed out mobile computing changed into making it more difficult to provide on-line safety, and 45 percent said the "consumerization of IT" changed into a priority. The latter class contains current technologies that cross over from purchaser to enterprise markets, with pills changing laptops because the excellent subject. As users carry pills into the enterprise and entry the company community, it is faced with the challenge of retaining elegant company records on those endpoints.

click to Tweet: Symantec launches DLP for pill: http://bit.ly/nRY66h

Symantec facts Loss Prevention for pill will permit clients to design the most of the drugs they are disturbing while monitoring and controlling the transmission of personal facts from these instruments with content material focus. The product is designed to allow organizations to lead labor and personal exhaust at the identical time as across company and personal e mail, internet communications, and customary functions attainable for the iPad. The insurance policy will extend to the tackle and counsel on it regardless of whether the consumer is related by the exhaust of 3G or Wi-Fi. benefit for the Android pill working gadget is additionally scheduled to be purchasable next 12 months.

Symantec records Loss Prevention for pill could be the newest addition to Symantec DLP and cellular administration options. The product is designed to let current Symantec DLP consumers leverage their current investment via employing the identical guidelines and administration infrastructure. The company additionally offers a complete set of encryption solutions ranging from replete disk encryption and detachable storage to email and server solutions. These consist of the currently introduced Symantec PGP Viewer for iOS. The viewer makes it feasible for employees of organizations with Symantec PGP commonplace Server in vicinity to read encrypted messages on their favored Apple iOS instruments including the iPad and iPhone as an example, govt group contributors can acquire and contemplate about encrypted copies of a sales file with assurance that both its privacy and security are intact.

prices"With the big boom in tablet adoptions, purchasers beget struggled the pass to lengthen assistance protection to this current consumer instrument because it makes its pass onto the traffic networks," referred to artwork Gilliland, senior vice chairman, assistance protection neighborhood, Symantec. "Symantec statistics Loss Prevention for pill will allow IT to superior benefit their companies in adopting this current know-how, whereas besides holding mighty protections for their elegant tips."

"while CISOs and security companies requisite to be seen as enterprise enablers who embody the newest productivity equipment, first they should be capable of be certain the private information on these gadgets may be blanketed," mentioned Jon Oltsik, foremost analyst, traffic approach group. "The extension of DLP merits to the most recent corporate endpoint, the iPad, will benefit them to meet both sides of the equation."

Availability and Pricing Symantec facts Loss Prevention for tablet is expected to be obtainable for the iPad in early 2012. The product might be priced per tablet. benefit for the Android tablet working system is scheduled to comply with. Symantec PGP Viewer for iOS is an Apple iOS software at the minute attainable for down load from the Apple App keep.

related

connect with Symantec

About Symantec Symantec is a world chief in presenting security, storage and methods management options to assist patrons and companies at ease and exploit their suggestions-driven world. Their software and functions present protection to in opposition t greater dangers at greater facets, more absolutely and effectively, enabling assurance anyplace information is used or stored. more counsel is available at www.symantec.com.

Story continues

ahead searching Statements: Any forward-searching indication of plans for items is preparatory and total future unencumber dates are tentative and are topic to trade. Any future liberate of the product or planned changes to product capability, performance, or feature are sphere to ongoing contrast via Symantec, and may or may additionally no longer be applied and will no longer be regarded enterprise commitments by pass of Symantec and should no longer be relied upon in making deciding to buy selections.

word TO EDITORS: if you would enjoy additional information on Symantec organisation and its items, gladden talk over with the Symantec information elbowroom at http://www.symantec.com/news. total expenditures illustrious are in U.S. greenbacks and are legitimate only within the u.s..

Symantec and the Symantec emblem are logos or registered emblems of Symantec organisation or its associates within the U.S. and other nations. different names may be trademarks of their respective house owners.

Technorati TagsSymantec, drugs, records loss prevention, iPad facts protection, information breach, information coverage


While it is very arduous task to elect reliable certification questions / answers resources with respect to review, reputation and validity because people assemble ripoff due to choosing wrong service. Killexams.com design it confident to serve its clients best to its resources with respect to exam dumps update and validity. Most of other's ripoff report complaint clients forward to us for the brain dumps and pass their exams happily and easily. They never compromise on their review, reputation and trait because killexams review, killexams reputation and killexams client assurance is necessary to us. Specially they buy care of killexams.com review, killexams.com reputation, killexams.com ripoff report complaint, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. If you perceive any counterfeit report posted by their competitors with the cognomen killexams ripoff report complaint internet, killexams.com ripoff report, killexams.com scam, killexams.com complaint or something enjoy this, just withhold in repartee that there are always tainted people damaging reputation of august services due to their benefits. There are thousands of satisfied customers that pass their exams using killexams.com brain dumps, killexams PDF questions, killexams exercise questions, killexams exam simulator. Visit Killexams.com, their sample questions and sample brain dumps, their exam simulator and you will definitely know that killexams.com is the best brain dumps site.

Back to Brain dumps Menu


050-728 questions and answers | 642-584 bootcamp | 70-332 actual questions | 050-ENVCSE01 pdf download | 70-767 exercise questions | HH0-130 sample test | M2010-727 exercise test | 1Z0-516 exam questions | 922-093 study guide | E22-214 braindumps | C2010-657 test prep | HP2-K26 exercise Test | 000-M235 actual questions | C9560-654 questions and answers | 920-328 dump | LOT-805 brain dumps | 000-562 braindumps | 000-M248 study guide | FN0-202 braindumps | M2040-669 VCE |


Take a gander at these ST0-116 actual question and answers
We are doing battle to giving you actual Symantec Data Loss Prevention 11(R) Technical Assessment exam questions and answers, alongside explanations. Each actual questions on killexams.com has been confirmed by Symantec certified specialists. They are exceptionally qualified and confirmed people, who beget numerous times of expert experience identified with the Symantec exams.

We beget their specialists operating ceaselessly for the gathering of actual test questions of ST0-116. total the pass4sure Questions and Answers of ST0-116 collected by their team are verified and updated by their Symantec certified team. they beget an approach to linger connected to the candidates appeared within the ST0-116 exam to induce their reviews regarding the ST0-116 exam, they beget an approach to collect ST0-116 exam tips and tricks, their expertise regarding the techniques utilized in the necessary ST0-116 exam, the mistakes they wiped out the necessary exam then improve their braindumps consequently. Click http://killexams.com/pass4sure/exam-detail/ST0-116 Once you tolerate their pass4sure Questions and Answers, you will feel assured regarding total the topics of exam and feel that your information has been greatly improved. These killexams.com Questions and Answers are not simply exercise questions, these are actual test Questions and Answers that are enough to pass the ST0-116 exam first attempt. killexams.com Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for total exams on website PROF17 : 10% Discount Coupon for Orders larger than $69 DEAL17 : 15% Discount Coupon for Orders larger than $99 SEPSPECIAL : 10% Special Discount Coupon for total Orders If you are inquisitive about success passing the Symantec ST0-116 exam to commence earning? killexams.com has forefront developed Symantec Data Loss Prevention 11(R) Technical Assessment test questions that will design confident you pass this ST0-116 exam! killexams.com delivers you the foremost correct, current and latest updated ST0-116 exam questions and out there with a 100 percent refund guarantee. There are several firms that present ST0-116 brain dumps however those are not reform and latest ones. Preparation with killexams.com ST0-116 current questions will be a best thing to pass this certification test in straightforward means.

killexams.com beget their experts Team to guarantee their Symantec ST0-116 exam questions are dependably the most current. They are at the total extraordinarily chummy with the exams and testing consciousness.

How killexams.com maintain Symantec ST0-116 exams updated?: they beget their uncommon procedures to realize the maximum recent exams statistics on Symantec ST0-116. Now after which they palpate their accomplices who're especially at ease with the exam simulator recognition or once in a while their customers will email us the latest enter, or they were given the most current update from their dumps carriers. When they learn the Symantec ST0-116 exams changed then they updates them ASAP.

On the off prep that you honestly forward up quick this ST0-116 Symantec Data Loss Prevention 11(R) Technical Assessment and might elect no longer to sit tight for the updates then they will give you replete refund. however, you should route your score answer to us with the goal that they will beget a exam. They will give you replete refund quick amid their working time when they assemble the Symantec ST0-116 score document from you.

Symantec ST0-116 Symantec Data Loss Prevention 11(R) Technical Assessment Product Demo?: they beget both PDF model and Testing Software. You can exam their product web page to perceive what it would look that like.

At the point when will I assemble my ST0-116 cloth once I pay?: Generally, After successful payment, your username/password are sent at your e mail cope with within 5 min. It may besides buy little longer in case your answers postpone in pervade authorization.

killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for total tests on website
PROF17 : 10% Discount Coupon for Orders extra than $69
DEAL17 : 15% Discount Coupon for Orders extra than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for total Orders


ST0-116 Practice Test | ST0-116 examcollection | ST0-116 VCE | ST0-116 study guide | ST0-116 practice exam | ST0-116 cram


Killexams EE0-021 actual questions | Killexams 351-050 VCE | Killexams HP0-J14 study guide | Killexams 117-302 free pdf | Killexams HPE6-A43 free pdf | Killexams HP2-B85 bootcamp | Killexams 000-646 pdf download | Killexams P5050-031 exercise Test | Killexams HP3-C35 cheat sheets | Killexams ST0-303 actual questions | Killexams 000-M01 questions answers | Killexams HP2-E27 exercise test | Killexams MB3-208 exercise test | Killexams 00M-662 study guide | Killexams TB0-110 dumps | Killexams M8060-655 exam prep | Killexams TMPTE dump | Killexams 00M-604 test questions | Killexams HP0-621 braindumps | Killexams 000-314 exam prep |


Exam Simulator : Pass4sure ST0-116 VCE Exam Simulator

View Complete list of Killexams.com Brain dumps


Killexams 70-343 dumps questions | Killexams 1Z0-430 actual questions | Killexams 000-997 exam prep | Killexams M2020-745 exercise Test | Killexams HP0-815 actual questions | Killexams ICDL-EXCEL braindumps | Killexams 9A0-384 brain dumps | Killexams 3M0-212 exercise test | Killexams 000-886 exercise questions | Killexams 9L0-504 exercise questions | Killexams JN0-411 questions answers | Killexams HP5-H01D exercise exam | Killexams 000-851 braindumps | Killexams HP2-E47 free pdf download | Killexams 00M-235 test questions | Killexams 1Z1-514 free pdf | Killexams 9A0-318 mock exam | Killexams AVA questions and answers | Killexams 000-M75 brain dumps | Killexams HP0-D14 study guide |


Symantec Data Loss Prevention 11(R) Technical Assessment

Pass 4 confident ST0-116 dumps | Killexams.com ST0-116 actual questions | http://heckeronline.de/

Identiv's (INVE) CEO Steven Humphreys on Q4 2017 Results - Earnings convoke Transcript | killexams.com actual questions and Pass4sure dumps

No result found, try current keyword!Add to this their first acquisition in years of 3VR [Technical hardship ... more RFID transponders, more loss prevention platforms. But longer term when you contemplate about it, the actual problem in securit...

2018 Digital Health Year in Review: Focus on care Coordination and Reimbursement | killexams.com actual questions and Pass4sure dumps

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to their website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to their services (such as their email digests or author tools)(our "Services"). By using their Website and registering for one of their Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of their Services, you can design choices about how they collect, exhaust and share your information through their Privacy headquarters under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for their Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country
  • Other Information: They besides collect other information you may voluntarily provide. This may include content you provide for publication. They may besides receive your communications with others through their Website and Services (such as contacting an author through their Website) or communications directly with us (such as through email, feedback or other forms or sociable media). If you are a subscribed user, they will besides collect your user preferences, such as the types of articles you would enjoy to read.

    Information from third parties (such as, from your employer or LinkedIn): They may besides receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you elect to exhaust LinkedIn to subscribe to their Website and Services, they besides collect information related to your LinkedIn account and profile.

    Your interactions with their Website and Services: As is just of most websites, they assemble certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. They exhaust this information to dissect trends, to administer the Website and their Services, to improve the content and performance of their Website and Services, and to track users' movements around the site. They may besides link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. They besides exhaust cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may exhaust on their Website and Services gladden perceive their "Cookies Guide" page.

    How finish they exhaust this information?

    We exhaust the information and data they collect principally in order to provide their Website and Services. More specifically, they may exhaust your personal information to:

  • Operate their Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about their policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of their Website and Services;
  • Conduct research and similar activities to improve their Website and Services; and
  • Comply with their legal and regulatory responsibilities and to enforce their rights.
  • How is your information shared?
  • Content and other public information (such as an author profile) is shared on their Website and Services, including via email digests and sociable media feeds, and is accessible to the generic public.
  • If you elect to exhaust their Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to benefit them to improve their content.
  • Our Website may present you the opportunity to share information through their Website, such as through Facebook's "Like" or Twitter's "Tweet" button. They present this functionality to benefit generate interest in their Website and content and to permit you to recommend content to your contacts. You should be alert that sharing through such functionality may result in information being collected by the applicable sociable media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be topic to such third party sociable media network's privacy policy.
  • Your information may besides be shared to parties who advocate their business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where they believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect their rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To their affiliated entities and in connection with the sale, assignment or other transfer of their company or their business.
  • How They Protect Your Information

    JD Supra takes reasonable and preempt precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. They restrict access to user information to those individuals who reasonably requisite access to achieve their job functions, such as their third party email service, customer service personnel and technical staff. You should withhold in repartee that no Internet transmission is ever 100% secure or error-free. Where you exhaust log-in credentials (usernames, passwords) on their Website, gladden recollect that it is your responsibility to safeguard them. If you believe that your log-in credentials beget been compromised, gladden contact us at privacy@jdsupra.com.

    Children's Information

    Our Website and Services are not directed at children under the age of 16 and they finish not knowingly collect personal information from children under the age of 16 through their Website and/or Services. If you beget judgement to believe that a child under the age of 16 has provided personal information to us, gladden contact us, and they will endeavor to delete that information from their databases.

    Links to Other Websites

    Our Website and Services may accommodate links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using their Website or Services and click a link to another site, you will leave their Website and this Policy will not apply to your exhaust of and activity on those other sites. They inspirit you to read the legal notices posted on those sites, including their privacy policies. They are not liable for the data collection and exhaust practices of such other sites. This Policy applies solely to the information collected in connection with your exhaust of their Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

    Information for EU and Swiss Residents

    JD Supra's principal locality of traffic is in the United States. By subscribing to their website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, they rely on their legitimate interests in order to process your personal information. For example, they rely on this legal ground if they exhaust your personal information to manage your Registration Data and administer their relationship with you; to deliver their Website and Services; understand and improve their Website and Services; report reader analytics to their authors; to personalize your experience on their Website and Services; and where necessary to protect or safeguard their or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. gladden perceive Article 6(1)(f) of the E.U. generic Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). gladden perceive the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that they limit or abstain from processing your personal information.
  • Your Rights
  • Right of Access/Portability: You can inquireof to review details about the information they hold about you and how that information has been used and disclosed. Note that they may request to verify your identification before fulfilling your request. You can besides request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
  • Right to reform Information: You may inquireof that they design corrections to any information they hold, if you believe such correction to be necessary.
  • Right to Restrict Their Processing or Erasure of Information: You besides beget the privilege in certain circumstances to inquireof us to restrict processing of your personal information or to erase your personal information. Where you beget consented to their exhaust of your personal information, you can withdraw your consent at any time.
  • You can design a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

    Privacy OfficerJD Supra, LLC10 Liberty Ship Way, Suite 300Sausalito, California 94965

    You can besides manage your profile and subscriptions through their Privacy headquarters under the "My Account" dashboard.

    We will design total practical efforts to respect your wishes. There may be times, however, where they are not able to fulfill your request, for example, if applicable law prohibits their compliance. gladden note that JD Supra does not exhaust "automatic conclusion making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: They will retain your personal information in a contour that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. They may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and topic to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When they beget no ongoing legitimate traffic requisite to process your personal information, they will either delete or anonymize it, or, if this is not feasible (for example, because your personal information has been stored in backup archives), then they will securely store your personal information and sequester it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As illustrious in the "How They share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, they beget ensured that such third parties beget either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process total personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they beget been subjected to strict contractual provisions in their contract with us to guarantee an adequate even of data protection for your data.
  • California Privacy Rights

    Pursuant to Section 1798.83 of the California Civil Code, their customers who are California residents beget the privilege to request certain information regarding their disclosure of personal information to third parties for their direct marketing purposes.

    You can design a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

    Privacy OfficerJD Supra, LLC10 Liberty Ship Way, Suite 300Sausalito, California 94965

    Some browsers beget incorporated a finish Not Track (DNT) feature. These features, when turned on, route a signal that you prefer that the website you are visiting not collect and exhaust data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, they currently finish not respond to DNT signals on their site.

    Access/Correct/Update/Delete Personal Information

    For non-EU/Swiss residents, if you would enjoy to know what personal information they beget about you, you can route an e-mail to privacy@jdsupra.com. They will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. They will respond within 30 days to your request for access to your personal information. In some cases, they may not be able to remove your personal information, in which case they will let you know if they are unable to finish so and why. If you would enjoy to reform or update your personal information, you can manage your profile and subscriptions through their Privacy headquarters under the "My Account" dashboard. If you would enjoy to delete your account or remove your information from their Website and Services, route an e-mail to privacy@jdsupra.com.

    Changes in Their Privacy Policy

    We reserve the privilege to change this Privacy Policy at any time. gladden mention to the date at the top of this page to determine when this Policy was last revised. Any changes to their Privacy Policy will become efficient upon posting of the revised policy on the Website. By continuing to exhaust their Website and Services following such changes, you will be deemed to beget agreed to such changes.

    Contacting JD Supra

    If you beget any questions about this Privacy Policy, the practices of this site, your dealings with their Website or Services, or if you would enjoy to change any of the information you beget provided to us, gladden contact us at: privacy@jdsupra.com.

    As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and their services (such as their email article digests)(our "Services") exhaust a touchstone technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are little data files that are transferred to your computer when you exhaust their Website and Services. These technologies automatically identify your browser whenever you interact with their Website and Services.

    How They exhaust Cookies and Other Tracking Technologies

    We exhaust cookies and other tracking technologies to:

  • Improve the user experience on their Website and Services;
  • Store the authorization token that users receive when they login to the private areas of their Website. This token is specific to a user's login session and requires a convincing username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  • Track anonymous site usage; and
  • Permit connectivity with sociable media networks to permit content sharing.
  • There are different types of cookies and other technologies used their Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and evanesce from your computer or device when you nigh your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies linger on your computer or device after your browser has been closed and last for a time specified in the cookie. They exhaust persistent cookies when they requisite to know who you are for more than one browsing session. For example, they exhaust them to recollect your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of their web pages and emails may besides accommodate little electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically labor in conjunction with cookies to collect data. They exhaust these images to identify their users and user behavior, such as counting the number of users who beget visited a web page or acted upon one of their email digests.
  • JD Supra Cookies. They locality their own cookies on your computer to track certain information about you while you are using their Website and Services. For example, they locality a session cookie on your computer each time you visit their Website. They exhaust these cookies to allow you to log-in to your subscriber account. In addition, through these cookies they are able to collect information about how you exhaust the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting their Website and the URL you next visit (even if those URLs are not on their Website). They besides utilize email web beacons to monitor whether their emails are being delivered and read. They besides exhaust these tools to benefit deliver reader analytics to their authors to give them insight into their readership and benefit them to improve their content, so that it is most useful for their users.

    Analytics/Performance Cookies. JD Supra besides uses the following analytic tools to benefit us dissect the performance of their Website and Services as well as how visitors exhaust their Website and Services:

  • HubSpot - For more information about HubSpot cookies, gladden visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on current Relic cookies, gladden visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across total websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.
  • Facebook, Twitter and other sociable Network Cookies. Their content pages allow you to share content appearing on their Website and Services to your sociable media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, they embed code that such third party sociable networks provide and that they finish not control. These buttons know that you are logged in to your sociable network account and therefore such sociable networks could besides know that you are viewing the JD Supra Website.

    Controlling and Deleting Cookies

    If you would enjoy to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can finish so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject total cookies, only accept certain types of cookies, or prompt you every time a site wishes to reclaim a cookie. It's besides light to delete cookies that are already saved on your device by a browser.

    The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to finish so with a particular browser, you can exhaust your browser's "Help" role or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

    Updates to This Policy

    We may update this cookie policy and their Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. They may besides notify you of changes to their privacy policy by email.

    Contacting JD Supra

    If you beget any questions about how they exhaust cookies and other tracking technologies, gladden contact us at: privacy@jdsupra.com.


    Carrier Testing for ascetic Childhood Recessive Diseases by Next-Generation Sequencing | killexams.com actual questions and Pass4sure dumps

    Introduction

    Preconception testing of motivated populations for recessive disease mutations, together with education and genetic counseling of carriers, can markedly reduce disease incidence within a generation. Tay-Sachs disease [TSD; Online Mendelian Inheritance in Man (OMIM) accession number 272800], for example, is an autosomal recessive neurodegenerative disorder with onset of symptoms in infancy and death by 2 to 5 years of age. Formerly, the incidence of TSD was 1 per 3600 Ashkenazi births in North America (1, 2). After 40 years of preconception screening in this population, however, the incidence of TSD has been reduced by more than 90% (2–5). Although TSD remains incurable, therapies are available for many ascetic recessive diseases of childhood. Thus, in addition to disease prevention, preconception testing could enable perinatal diagnosis and treatment, which can profoundly diminish disease severity.

    Although individual Mendelian diseases are uncommon in generic populations, collectively, they account for ~20% of infant mortality and ~10% of pediatric hospitalizations (6, 7). Over the past 25 years, 1139 genes that occasions Mendelian recessive diseases beget been identified (8). To date, however, preconception carrier testing has been recommended in the United States only for five of these: fragile X syndrome (OMIM #300624) in selected individuals; cystic fibrosis (OMIM #219700) in Caucasians; and TSD, Canavan disease (OMIM #271900), and familial dysautonomia (OMIM #223900) in individuals of Ashkenazi descent (9–13). A framework for the progress of criteria for comprehensive preconception screening can be inferred from an American College of Medical Genetics (ACMG) report on expansion of newborn screening for inherited diseases (14). Criteria included test accuracy and cost, disease severity, highly penetrant recessive inheritance, and whether an intervention was available for those identified. These criteria are besides apposite for expansion of preconception carrier screening. Hitherto, necessary criteria precluding extension of preconception screening to most ascetic recessive mutations or the generic population beget been cost [defined in that report as an overall analytical cost requirement of <$1 per test per condition (14)] and the absence of accurate, sensitive, scalable technologies.

    Target capture and next-generation sequencing (NGS) beget shown efficacy and, recently, scalability for resequencing human genomes and exomes, providing an alternative potential paradigm for comprehensive carrier testing (15–22). In genome research, an middling depth of sequence coverage of 30-fold has been accepted as sufficient for single-nucleotide polymorphism (SNP) and nucleotide insertion or deletion (indel) detection (15–22). However, acceptable false-positive and false-negative rates for routine exhaust in clinical exercise are more stringent and are driven by the intended purpose for which the data are to be used. Data demonstrating the sensitivity and specificity of genotyping of disease mutations, particularly polynucleotide indels, indecent insertions and deletions, copy number variations (CNVs), and complex rearrangements, are very limited (20–22). In particular, the accuracy of disease mutation genotypes derived from NGS of enriched targets has been uncertain.

    A recent workshop provided recommendations for qualification of current methodologies for broader population-based carrier screening (23). These were tall analytical validity, concordance in many settings, tall throughput, and cost-effectiveness (including sample acquisition and preparation). Here, they report the progress of a preconception carrier screen for 448 ascetic recessive childhood disease genes, based on target enrichment and NGS that meets most of these criteria, and exhaust of the screen to assess carrier tribulation for ascetic recessive diseases of childhood.

    Results Disease inclusion

    The carrier test reported herein was based on several hypotheses. First, cost-effectiveness was assumed to be faultfinding for test adoption. The incremental cost associated with increasing the degree of multiplexing was assumed to dwindle toward an asymptote. Thus, very broad coverage of diseases was assumed to present optimal cost-benefit. Second, comprehensive mutation sets, allele frequencies in populations, and individual mutation genotype-phenotype relationships beget been defined in very few recessive diseases. In addition, some studies of cystic fibrosis carrier screening for a few common alleles beget shown decreased prevalence of tested alleles with time, rather than reduced disease incidence (24, 25). These two lines of evidence suggested that very broad coverage of mutations offered the greatest likelihood of substantial reductions in disease incidence with time. Third, physician, patient, and societal adoption of screening was assumed to be optimal for the most ascetic and highly penetrant childhood diseases, before conception and where the anticipated clinical validity and clinical utility of testing was clear (26). Therefore, diseases were chosen that would almost certainly change family planning by prospective parents or strike antenatal, perinatal, or neonatal care. Milder recessive disorders, such as deafness, and adult-onset diseases, such as inherited cancer syndromes, were omitted, as were conditions lacking stalwart evidence for causal mutations (26).

    Database and literature searches and expert reviews were performed on 1123 diseases with recessive inheritance of known molecular basis (8, 27, 28). In general, diseases were selected to meet ACMG guidelines for genetic testing for rare, highly penetrant disorders (26). Assessment of the clinical validity and utility of testing was primarily based on literature review and was challenging for some disorders because of the paucity of data. Several subordinate requirements were gathered: In view of pleiotropy and variable severity, disease genes were included if mutations caused ascetic illness in a harmony of affected children. total but six diseases that featured genocopies (including variable inheritance and mitochondrial mutations) were included. Diseases were not excluded on the basis of low incidence. Diseases for which big population carrier screens exist were included, such as TSD, hemoglobinopathies, and cystic fibrosis. Mental retardation genes were not included in this iteration. Four hundred and forty-eight X-linked recessive and autosomal recessive diseases, encompassing 437 genes, met these criteria (table S1). The disease nature was cardiac for 8, cutaneous for 45, developmental for 46, endocrine for 15, gastroenterological for 3, hematological for 15, hepatic for 3, immunological for 29, metabolic for 142, neurological for 122, ocular for 12, renal for 25, respiratory for 8, and skeletal for 28. Note that these genes, although a august representative set, require further assessment of clinical readiness before translation into clinical testing.

    Technology selection

    Array hybridization with allele-specific primer extension was initially favored for expanded carrier detection because of test simplicity, cost, scalability, and accuracy, as has recently been described (29). To be well suited for array-based screening, however, most carriers must be accounted for by a few mutations, and most disease mutations must be nucleotide substitutions (8, 27, 28). Of 215 autosomal recessive disorders examined, only 87 were assessed to meet these criteria. Most recessive disorders for which a big harmony of tribulation was attributable to a few disease mutations were limited to specific ethnic groups. Indeed, 286 ascetic childhood autosomal recessive diseases encompassed 19,640 known disease mutations (8, 27, 28). Given that the Human Gene Mutation Database (HGMD) lists 102,433 disease mutations (27), a number that is steadily increasing, a fixed-content routine appeared impractical. Other concerns with array-based screening for recessive disorders were nature 1 errors in the absence of confirmatory testing and nature 2 errors for disease mutations other than substitutions (complex rearrangements, indels, or indecent deletions with uncertain boundaries). A serendipitous discovery (discussed below) that supported this conclusion was an unexpectedly tall number of characterized mutations that are misannotated.

    The effectiveness and remarkable decline in cost of exome capture and NGS for variant detection in genomes and exomes suggested an alternative potential paradigm for comprehensive carrier testing. Four target enrichment and three NGS methods were preliminarily evaluated for multiplexed carrier testing. preparatory experiments suggested that existing protocols for Agilent SureSelect hybrid capture (15) and RainDance microdroplet polymerase chain reaction (PCR) (16) but not Febit HybSelect microarray-based biochip capture (30) or Olink padlock probe ligation and PCR (31) yielded consistent target enrichment. Therefore, workflows and software pipelines were developed for comprehensive carrier testing by hybrid capture or microdroplet PCR, followed by NGS (Fig. 1). Baits or primers were designed to capture or amplify 1,978,041 nucleotides (nt), corresponding to 7717 segments of 437 recessive disease genes by hybrid capture and microdroplet PCR, respectively. Targeted were total coding exons and splice site junctions, and intronic, regulatory, and untranslated regions known to accommodate disease mutations (table S2). In general, baits for hybrid capture or PCR primers were designed to encompass or flank disease mutations, respectively. Primers were besides designed to avoid known polymorphisms and to minimize nontarget nucleotides. To capture or amplify both the natural and the disease mutation alleles, they besides designed custom baits or primers for 11 indecent deletion disease mutations for which boundaries had been defined (table S3). A total of 29,891 120-mer RNA baits were designed to capture 98.7% of targets. Fifty-five percent of 101 exons that failed bait design contained reiterate sequences (table S4). Primer pairs (10,280) were designed to amplify 99% of targets (table S5). Twenty exons failed primer design by falling outside the amplicon size purview of 200 to 600 nt.

    Fig. 1

    Workflow of the comprehensive carrier screening test. Workflow shows receiving samples and DNA extraction, target enrichment from DNA samples, multiplexed sequencing library preparation, NGS, and bioinformatic analysis. (The bioinformatic conclusion tree is shown in fig. S4.)

    Analytic metrics

    An pattern target enrichment protocol would inexpensively result in at least 30% of nucleotides being on target, which corresponded to ~500-fold enrichment with ~2-million-nucleotide target size. This was achieved with hybrid capture after one round of bait redesign for underrepresented exons and decreased bait representation in overrepresented exons (Table 1). An pattern target enrichment protocol would besides give a narrow distribution of target coverage and without tails or skewness (indicative of minimal enrichment-associated bias). After hybrid capture, the sequencing library size distribution was narrow (Fig. 2A). The aligned sequence coverage distribution was unimodal but flat (platykurtic) and right-skewed (Fig. 2B). This implied that hybrid capture would require oversequencing of most targets to recruit a minority of poorly selected targets to adequate coverage. As expected, median coverage increased linearly with sequence depth. The harmony of bases with greater than zero and >20× coverage increased toward asymptotes at ~99 and ~96%, respectively (Table 1 and Fig. 2C). Targets with low (<3×) coverage were highly reproducible and had tall GC content (table S6). This suggested that targets failing hybrid capture could be predicted and, perhaps, rescued by individual PCRs.

    Table 1

    Sequencing, alignment, and coverage statistics for target enrichment and sequencing platforms.

    Fig. 2

    Analytic metrics of multiplexed carrier testing by NGS. (A) Chromatograms of size distributions of sequencing libraries after target enrichment. Top: Target enrichment by hybrid capture. Bottom: Target enrichment by microdroplet PCR. Size markers are shown at 40 and 8000 nt. FU, fluorescence units. (B) Frequency distribution of target coverage after hybrid selection and 1.75 Gb of singleton 50-mer Illumina GAIIx SBS of sample NA13675. Aligned sequences had a trait score of >25. (C) Target coverage as a role of depth of sequencing across 104 samples and six experiments. (D) Frequency distribution of target coverage after microdroplet PCR and 1.49 Gb of singleton 50-mer SBS of sample NA20379. Aligned sequences had a trait score of >25.

    Given the requisite for highly accurate carrier detection, they required >10 uniquely aligned reads of trait score >20 and >14% of reads to convoke a variant (20, 21). The requirement for >10 reads was highly efficient for nucleotides with temper coverage. For heterozygote detection, for example, this was equivalent to ~20× coverage, which was achieved in ~96% of exons with ~2.6 gigabases (Gb) of sequence (Fig. 2C). The harmony of targets with at least 20× coverage appeared to be useful for trait assessment. The requirement for ≥14% of reads to convoke a variant was highly efficient for nucleotides with very tall coverage and was derived from the genotype data discussed below. A trait score requirement was necessary when NGS started, but is now largely redundant.

    In theory, microdroplet PCR should result in total cognate amplicons being on target and should induce minimal bias. In practice, the coverage distribution was narrower than hybrid capture but with similar privilege skewing (Fig. 2D). However, these results were complicated by ~11% recurrent primer synthesis failures. This resulted in linear amplification of a subset of targets, ~5% of target nucleotides with zero coverage and a similar harmony of nucleotides on target to that obtained in the best hybrid capture experiments (~30%; Table 1). Hybrid capture was used for subsequent studies for reasons of cost.

    Multiplexing of samples during hybrid selection and NGS had not previously been reported. Six- and 12-fold multiplexing was achieved by adding molecular bar codes to adaptor sequences. Interference of bar code nucleotides with hybrid selection did not occur appreciably: The stoichiometry of multiplexed pools was essentially unchanged before and after hybrid selection. Multiplexed hybrid selection was establish to be ~10% less efficient than singleton selection, as assessed by median fold enrichment. Less than 1% of sequences were discarded at alignment because of bar code sequence ambiguity. Therefore, up to 12-fold multiplexing at hybrid selection and per sequencing lane (equivalent to 96-plex per sequencing tide cell) was used in subsequent studies to achieve the targeted cost of <$1 per test per sample.

    Several NGS technologies are currently available. Of these, the Illumina sequencing-by-synthesis (SBS) and SOLiD sequencing-by-ligation (SBL) platforms are widely disseminated and beget throughput of at least 50 Gb per race and read lengths of at least 50 nt. Therefore, the trait and quantity of sequences from multiplexed, target-enriched libraries were compared with SBS (GAIIx singleton 50-mer) and SBL (SOLiD3 singleton 50-mer; Table 1). SBS- and SBL-derived 50-mer sequences (and alignment algorithms) gave similar alignment metrics (Table 1). When compared with Infinium array results, specificity of SNP genotypes by SBS and SBL was very similar (SBS, 99.69%; SBL, 99.66%), reflecting both target enrichment and multiplexed sequencing (Fig. 3).

    Fig. 3

    Venn diagrams of specificity of on-target SNP calls and genotypes in six samples. Target nucleotides were enriched by hybrid selection and sequenced by Illumina GAIIx SBS and SOLiD3 SBL at sixfold multiplexing. The samples were besides genotyped with Infinium Omni1-Quad SNP arrays. (A) Comparison of SNP calls and genotypes obtained by SBS, SBL, and arrays at nucleotides surveyed by total three methods. SNPs were called if present in >10 uniquely aligning SBS reads, >14% of reads, and with middling trait score of >20. Heterozygotes were identified if present in 14 to 86% of reads. Numbers mention to SNP calls. Numbers in brackets mention to SNP genotypes. (B) Comparison of SNP calls and genotypes obtained by SBS, SBL, and arrays. SNPs were called if present in more than four uniquely aligning SBS reads, >14% of reads, and with middling trait score of >20. Heterozygotes were identified if present in 14 to 86% of reads.

    Given approximate parity of throughput and accuracy, consideration was given to optimal read length. Unambiguous alignment of short-read sequences is typically confounded by repetitive sequences, but was not apposite for carrier testing, because targets overwhelmingly contained unique sequences. The number of mismatches tolerated for unique alignment of short-read sequences is highly constrained but increases with read length. The vast majority of disease mutations are single-nucleotide substitutions or little indels. However, comprehensive carrier testing besides requires detection of polynucleotide indels, indecent insertions, indecent deletions, and complex rearrangements. A combination of bioinformatic approaches was used to overcome short-read alignment shortcomings (Fig. 4). First, with the Illumina HiSeq SBS platform, they used the novel approach of read pair assembly before alignment (99% efficiency) to generate longer reads with high-quality scores (148.6 ± 3.8 nt combined read length and expand in nucleotides with trait score >30 from 75 to 83%). This was combined with generation of 150-nt sequencing libraries without gel purification by optimization of DNA shearing procedures and exhaust of silica membrane columns. Omission of gel purification was faultfinding for scalability of library generation. Second, they reduced the penalty on polynucleotide variants, rewarding identities (+1) and penalizing mismatches (−1) and indels [−1−log(indel − length)]. Third, indecent deletions were detected both by consummate alignment to mutant junction reference sequences and by local decreases in normalized coverage (normalized to total sequence generated; C. H. Hu, personal communication). Previous studies beget identified CNVs on the basis of changes in regional coverage along a chromosome in an individual sample (20, 21). However, concomitant analysis of normalized coverage in batches of samples appears to circumvent the requisite for adjustment for GC content (32), allowing more accurate detection of segmental losses. This was illustrated by identification of eight known indecent deletion disease mutations (Fig. 5). Furthermore, seeking consummate alignment to mutant junction reference sequences obviates low alignment scores when short reads containing polynucleotide variants are mapped to a natural reference. This was illustrated by identification of 11 indecent deletion mutations for which boundaries had been defined (table S3). It is anticipated that these approaches could be extended to indecent insertions and complex rearrangements but will require additional analytical validation.

    Fig. 4

    Decision tree to classify sequence variation and evaluate carrier status. After reads were aligned to references, substitution, insertion, and deletion events and their associated trait metrics were recorded. Variants were classified as heterozygous or homozygous and annotated by comparison with mutation databases. Variants not in the mutation databases were evaluated for putative functional consequence and were retained as disease mutations if predicted to result in protein truncation. Variants with a frequency of <5% among total samples and that were known to occasions a disease phenotype or loss of protein role and that were only establish as homozygous in affected individuals were retained and reported.

    Fig. 5

    Detection of indecent deletion mutations by local reduction in normalized aligned reads. (A) Deletion of CLN3 introns 6 to 8, 966bpdel, exons7-8del and fs, chr16:28405752_28404787del in four known compound heterozygotes (NA20381, NA20382, NA20383, and NA20384; red diamonds) and one undescribed carrier (NA00006; green diamond) among 72 samples sequenced. (B) Heterozygous deletion in HBA1 (chr16:141620_172294del, 30,676-bp deletion from 5′ of ζ2 to 3′ of θ1 in ALU regions) in one known (NA10798; red diamond; normalized coverage, 26; addupto normalized coverage, 61.9 ± 15.2) and two undescribed carriers [NA19193 (normalized coverage, 28) and NA01982 (normalized coverage, 31); green diamonds] among 72 samples. Heterozygous deletion in NA10798 was confirmed by array hybridization. (C) Known homozygous deletion of exons 7 and 8 of SMN1 in one of eight samples (NA03813; red diamond). (D) Detection of a indecent deletion that is a occasions of Duchenne burly dystrophy (OMIM #310200, DMD exons 51 to 55 del, chrX:31702000_31555711del) by reduction in normalized aligned reads at chrX:31586112. Among 72 samples, one (NA04364; red diamond) was from an affected male, and another (NA18540, a female JPT/HAN HapMap sample) was determined to carry a deletion that extends to at least chrX:31860199 [see (E)]. (E) An undescribed heterozygous deletion of DMD 3′ exon 44–3′ exon 50 (chrX:32144956-31702228del) in NA18540 (green diamond), a JPT/HAN HapMap sample. This deletion extends from at least chrX:31586112 to chrX:31860199 [see (D)]. Sample NA05022 (red diamond) is the uncharacterized mother of an affected son with 3′ exon 44–3′ exon 50 del, chrX:32144956-31702228del. Given the absence of the mutation in the mother, it likely occurred de novo in the son, as observed in one-third of DMD patients (62). (F) Hemizygous deletion in PLP1 exons3_4, c.del349_495del, chrX:102928207_102929424del in one (NA13434; red diamond) of eight samples. (G) Absence of indecent deletion CG984340 (ERCC6 exon 9, c.1993_2169del, 665_723del, exon 9 del, chr10:50360915_50360739del) in 72 DNA samples. The sample in red (NA01712) was incorrectly annotated to be a compound heterozygote with CG984340 on the basis of cDNA sequencing.

    Clinical metrics

    On the basis of these strategies and their previous experience of genotyping variants identified in next-generation genome and chromosome sequences (20, 21, 33, 34), a bioinformatic conclusion tree for genotyping disease mutations was developed (Fig. 4). Clinical utility of target enrichment, SBS sequencing, and this conclusion tree for genotyping disease mutations was assessed. SNPs in 26 samples were genotyped by both high-density arrays and sequencing. The distribution of read count–based allele frequencies of 92,106 SNP calls was trimodal, with peaks corresponding to homozygous reference alleles, heterozygotes, and homozygous variant alleles, as ascertained by array hybridization (Fig. 6B). Optimal genotyping cutoffs were 14 and 86% (Fig. 6B). With these cutoffs and a requirement for 20× coverage and 10 reads of trait ≥20 to convoke a variant, the accuracy of sequence-based SNP genotyping was 98.8%, sensitivity was 94.9%, and specificity was 99.99%. The positive predictive value (PPV) of sequence-based SNP genotypes was 99.96% and negative predictive value (NPV) was 98.5%, as ascertained by array hybridization. As sequence depth increased from 0.7 to 2.7 Gb, sensitivity increased from 93.9 to 95.6%, whereas PPV remained ~100% (Fig. 6A). Areas under the curve (AUCs) of the receiver operating characteristic (ROC) for SNP calls by hybrid capture and SBS were calculated. When genotypes in 26 samples were compared with genome-wide SNP array hybridization, the AUC was 0.97 when either the number or the percent reads calling a SNP were varied (Fig. 6, C and D). When the parameters were combined, the AUC was 0.99. For known substitution, indel, splicing, indecent deletion, and regulatory alleles in 76 samples, sensitivity was 100% (113 of 113 known alleles; table S7). The higher sensitivity for detection of known mutations reflected manual curation. The 20 known indels were confirmed by PCR and Sanger sequencing. Notably, substitutions, indels, splicing mutations, and indecent deletions account for the vast majority (96%) of annotated mutations (27).

    Fig. 6

    Clinical metrics of multiplexed carrier testing by NGS. (A) Comparison of 92,128 SNP genotypes by array hybridization with those obtained by target enrichment, SBS, and a bioinformatic conclusion tree in 26 samples. SNPs were called if present in >10 uniquely aligning reads, >14% of reads, and middling trait score of >20. Heterozygotes were identified if present in 14 to 86% of reads. TP = SNP called and genotyped correctly. TN = reference genotype called correctly. FN = SNP genotype undercall. FP = SNP genotype overcall. Accuracy = (TP + TN)/(TP + FN + TN + FP). Sensitivity = TP/(TP + FN). Specificity = TN/(TN + FP). Positive predictive value (PPV) = TP/(TP + FP). Negative predictive value (NPV) = TN/(TN + FN). (B) Distribution of allele frequencies of SNP calls by hybrid capture and SBS in 26 samples. Light blue, heterozygotes by array hybridization. (C) Receiver operating characteristic (ROC) curve of sensitivity and specificity of SNP genotypes by hybrid capture and SBS in 26 samples (when compared with array-based genotypes). Genomic regions with less than 20× coverage were excluded. Upon varying the number of reads calling the SNP, the locality under the curve (AUC) was 0.97. (D) ROC curve of SNP genotypes by hybrid capture and SBS in 26 samples. Genomic regions with less than 20× coverage were excluded. Upon varying the percent reads calling the SNP, AUC was 0.97.

    Unexpectedly, 14 of 113 literature-annotated disease mutations were either incorrect or incomplete (table S7) (35–,39). PCR and Sanger sequencing confirmed that the 14 variants and genotypes called by NGS were correct. For example, sample NA07092, from a masculine with X-linked recessive Lesch-Nyhan syndrome (OMIM #300322), was characterized as a deletion of HPRT1 exon 8 by complementary DNA (cDNA) sequencing (40), but had an explanatory splicing mutation (intron 8, IVS8+1_4delGTAA, chrX:133460381_133460384delGTAA; Fig. 7A). NA09545, from a masculine with XLR Pelizaeus-Merzbacher disease (PMD; OMIM #312080), characterized as a substitution disease mutation [PLP1 exon 5, c.767C>T, P215S (41)], was establish to besides feature PLP1 gene duplication [which is reported in 62% of sporadic PMD (42); Fig. 7B]. NA02057, from a female with aspartylglucosaminuria (OMIM #208400), characterized as a compound heterozygote, was homozygous for two adjacent substitutions (AGA exon 4, c.482G>A, R161Q, chr4:178596918G>A and exon 4, c.488G>C, C163S, chr4:178596912G>C in 38 of 39 reads; Fig. 8), of which C163S had been shown to be the disease mutation (43). Although one allele of NA01712, a CHT with Cockayne syndrome nature B (OMIM #133540), had been characterized by cDNA analysis as a deletion of ERCC6 exon 9 [c.1993_2169del, p.665_723del, exon 9 del, chr10:50360915_50360739del (44)], no dwindle in normalized exon 9 read number was observed despite more than 300× coverage (Fig. 5G). Instead, however, 64 of 138 NA01712 reads contained a nucleotide substitution that created a premature discontinue codon (Q664X, chr10:50360741C>T). Both ERCC4 mutations described in CHT NA03542 were absent in at least 130 aligning reads (44). However, the current study used DNA from Epstein-Barr virus (EBV)–transformed cell lines in which somatic hypermutation has been illustrious (45). In particular, ERCC4, a DNA repair gene, is a likely candidate for somatic mutation. Including these results, the specificity of sequence-based genotyping of substitution, indel, indecent deletion, and splicing disease mutations was 100% (97 of 97).

    Fig. 7

    Disease mutations and estimated carrier tribulation in 104 DNA samples. (A) Sample NA07092, from an affected masculine with X-linked recessive Lesch-Nyhan syndrome (OMIM #300322), had been characterized as a deletion of HPRT1 exon 8 by cDNA sequencing (19), but has an explanatory splicing mutation (intron 8, IVS8+1_4delGTAA, chrX:133460381_133460384delGTAA). (B) Sample NA09545, from an affected masculine with X-linked recessive Pelizaeus-Merzbacher disease (PMD; OMIM #312080), characterized as a substitution disease mutation [PLP1 exon 5, c.767C>T, P215S (20)], besides featured PLP1 gene duplication [which is reported in 62% of sporadic PMD (21)]. (C) Distribution of carrier tribulation of ascetic pediatric diseases among 104 DNA samples. (D) Ward hierarchical clustering of 227 ascetic pediatric disease mutations in 104 DNA samples.

    Fig. 8

    Five reads from NA202057 showing AGA exon 4, c.488G>C, C163S, chr4:178596912G>C and exon 4, c.482G>A, R161Q, chr4:178596918G>A (black arrows). One hundred and ninety-three of 400 reads contained these substitution disease mutations (CM910010 and CM910011). The top lines of doublets are Illumina GAIIx 50-nt reads. The bottom lines are NCBI reference genome, build 36.3. Colors depict trait (Q) scores of each nucleotide: red, >30; orange, 20 to 29; green, 10 to 19. Reads aligned uniquely to these coordinates.

    Carrier burden

    The middling carrier tribulation of ascetic recessive disease mutations for ascetic childhood recessive diseases was assessed in 104 DNA samples. total variants meeting the filtering criteria described above and flagged as disease mutations in HGMD were enumerated. Seventy-four percent of these, however, were accounted for by 47 substitutions each with an incidence of ≥5%, of which 20 were homozygous in samples unaffected by the corresponding disease (table S8). These were omitted. Literature advocate for pathogenicity was evaluated for the remaining variants flagged as disease mutations in HGMD. Variants were retained as disease mutations if they had been shown to result in loss of activity in a functional assay, were the only variants detected in affected individuals and absent in controls, and/or were predicted to result in a premature discontinue codon or loss of a substantial portion of the protein (Fig. 4). In total, 27% (122 of 460) of literature-cited disease mutations were omitted, because they were adjudged to be common polymorphisms or sequencing errors or because of a lack of evidence of pathogenicity. New, putatively deleterious variants (variants in ascetic pediatric disease genes that create premature discontinue codons or coding domain frameshifts) were quantified: 26 heterozygous or hemizygous current nonsense variants were identified in 104 samples (table S9). Including the latter, 336 variants were retained as likely disease mutations.

    The middling carrier tribulation of ascetic recessive substitutions, indels, and indecent deletion disease mutations, after exclusion of one allele in compound heterozygotes, was 2.8 per genome (291 in 104 samples). The carrier tribulation frequency distribution was unimodal with slight privilege skewing (Fig. 7C). The purview in carrier tribulation was surprisingly narrow (zero to seven per genome, with a mode of two; Fig. 7C).

    As exemplified by cystic fibrosis, the carrier incidence and mutation spectrum of individual recessive disorders vary widely among populations (46). However, whereas group sizes were small, no significant differences in total carrier tribulation were establish between Caucasians and other ethnicities, between males and females, nor between affected and unaffected individuals (after correction for compound heterozygosity in those affected). Hierarchical clustering of samples and disease mutations revealed an apparently random topology, suggesting that targeted population testing is likely to be ineffective (Fig. 7D). Adequacy of hierarchical clustering was attested to by samples from identical twins being nearest neighbors, as were two disease mutations in linkage disequilibrium.

    Discussion

    We beget described a screening test for carriers of 448 ascetic childhood recessive illnesses consisting of target enrichment, NGS, and bioinformatic analyses, which worked well in a research setting. Specificity was 99.96%, and a sensitivity of ~95% was attained with hybrid capture at a sequence depth of 2.5 Gb per sample. Because enrichment failures with hybrid capture were reproducible, they may be amenable to rescue by individual PCR or probe redesign. Alternatively, microdroplet PCR should theoretically achieve a sensitivity of ~99%, albeit at higher cost (16, 47). The test was scalable, modular, and amenable to automation, with batches of 192 samples and a turnaround of 2 weeks. The time to first result could be reduced substantially with microdroplet PCR and third-generation sequencing. At tall volume, the overall analytical cost of the hybrid enrichment-based test was $378, achieving the requirement of $1 per test per condition and approximating that expended on treatment of ascetic recessive childhood disorders per U.S. live birth (14, 29). Although the analytical cost will dwindle as the throughput of NGS improves, test interpretation, reporting, genetic counseling, and stewardship of mutation databases will consult considerable additional costs.

    Having established technical feasibility in a research setting, the next phases of carrier test progress will be refinement of the list of diseases, automation, software implementation, report development, and, most important, validation in a realistic testing situation featuring investigator blinding and less manual review. For example, genes associated with ascetic cognitive developmental disorders may merit inclusion. Although technical standards and guidelines beget been established for laboratory-developed genetic testing for rare disorders in accredited laboratories (26), there are several challenges in their adoption for NGS and bioinformatic-based testing of ~500 conditions. For example, specific national standards for trait assurance, trait control, test accessioning and reporting, and proficiency evaluation finish not currently exist. Addressing crucial issues such as specificity and counterfeit positives is complex when hundreds of genes are being sequenced simultaneously. For certain diseases, such as cystic fibrosis, reference sample panels and metrics beget been established. For diseases without such materials, it is prudent to test as many samples containing known mutations as possible. In setting up and validating the screen, it would besides be necessary to test examples of total classes of mutations and situations that are anticipated to be potentially problematic, such as mutations within tall GC content regions, simple sequence repeats, and repetitive elements.

    The ethical, legal, and sociable implications of comprehensive carrier testing warrant much discussion. These issues, in turn, are influenced by the scope and setting in which testing is proposed. The pattern age for recessive disease screening is in early adulthood and before pregnancy (48, 49). One possibility would be voluntary community-based population testing. This would beget an handicap over testing in a hospital setting, where information about carrier testing often is communicated during pregnancy or after the birth of an affected child (50). Community-based carrier testing has had tall uptake, without plain stigma or discrimination and with substantial reductions in the frequencies of tested disorders (3, 48, 49, 51–54). After stakeholder discussions, the cost-effectiveness and clinical utility of offering community-based carrier testing would require detailed assessment. Examination of the results of existing population-based carrier screening programs for TSD and cystic fibrosis could provide templates for such analyses.

    Rapid adoption of comprehensive carrier testing is likely by in vitro fertilization clinics, where screening of sperm and oocyte donors has tall clinical utility, lower counseling burden, and little incremental cost (55). Early adoption is besides likely in medical genetics clinics, where counseling resources already exist, to screen individuals with a family history of inherited disease. Although the data reported herein are preliminary, the plain random distribution of mutations in individuals argues against screening different populations for different diseases. The most significant hurdles to implementing comprehensive carrier screening will be facile interpretation of results, reporting in a manner comprehensible by physicians and patients, education of the public of the benefits and limitations of screening, and provision of genetic counselors.

    Currently, a two-stage approach is used for preconception carrier screening of couples, with confirmatory testing of total positive results. However, this has been in a setting of testing individual genes for specific mutations where positive results are rare. The requirement for at least 10 high-quality reads to substantiate a variant convoke resulted in a specificity of 99.96% for single-nucleotide substitutions (which is the limit of accuracy for the gold touchstone routine used) and 100% for about 200 known mutations and current indels in their screening method. It appeared, therefore, that confirmatory testing of total single-nucleotide substitutions and indels was unnecessary. Obviously, inclusion of controls in each test race and random sample retesting will be required. experience with polynucleotide indels, copy number variants, indecent insertions and deletions, and complex rearrangements is as yet insufficient to draw solid conclusions. However, detection of consummate alignments to mutant reference sequences appeared to be robust for identification of indecent insertions and deletions. They noted, however, that identification of larger polynucleotide indels was influenced in some sequences by the particular alignment seed, suggesting that additional refinement of alignment parameters is needed.

    We establish an unexpectedly tall harmony of literature-annotated disease mutations that were incorrect, incomplete, or common polymorphisms. Differentiation of common polymorphisms from disease mutations requires genotyping a big number of unaffected individuals. Severe, orphan disease mutations should be uncommon (<1% incidence) and should not be establish in the homozygous status in unaffected individuals. Unexpectedly, they establish that 74% of “disease mutation” calls were accounted for by substitutions with incidences of ≥5%, of which almost one-half were homozygous in samples unaffected by the corresponding disease. besides unexpected was the finding that 14 of 113 literature-annotated disease mutations were incorrect. Thus, for many recessive diseases, HGMD, dbSNP, OMIM, and the literature are insufficient arbiters of whether variants are disease mutations. They beget shown NGS of samples from affected individuals to be a powerful routine for error correction: More than three-quarters of errors in mutation identification were Sanger sequencing interpretation errors or incorrect imputation of genomic mutations from cDNA sequencing. Key advantages of NGS are clonal derivation (facilitating unambiguous detection of heterozygous and indel variants), maintenance of facet information (allowing haplotype derivation for adjacent variants), and highly redundant coverage (resulting in extremely low consensus error rates). Thus, although they beget shown that it is technically feasible to undertake comprehensive analysis of recessive gene sequences, sequencing of many unaffected and affected samples will be required to establish an authoritative disease mutation database. Specifically, current reference resources accommodate common polymorphisms that are annotated as disease mutations and erroneous disease mutations. Without reference database improvements, the clinical utility of comprehensive carrier testing will be limited. Aside from nonsense mutations and premature discontinue codons in known disease genes and the study of affected individuals, additional bioinformatic approaches will be needed to distinguish rare benign variants from pathogenic variants: Amino acid substitution characteristics such as physicochemical and evolutionary conservation and location (where tertiary structure is known) are useful but not definitive. For many rare variants, functional assays will requisite to be developed to assess pathogenicity rigorously. Establishment of an authoritative database of disease mutations is clearly needed and represents a nascent bottleneck in progress toward prevention, diagnosis, and treatment of recessive diseases. In the interim, clinical interpretation of the functional minute or pathogenicity of variants will be challenging for many recessive diseases.

    A first assay of the middling carrier tribulation of disease mutations (substitutions, indels, and indecent deletions) causing ascetic childhood recessive diseases was determined: In 104 unrelated individuals, it was 2.8 per genome. Several qualifications of this tribulation assay should be noted. First, as discussed, an adequate compilation of pathogenic mutations does not currently exist, and stalwart evidence of pathogenicity was absent for some of the variants referred to as disease mutations. Second, the tribulation assay excluded new, rare, missense variants of unknown significance (VUSs), some of which are likely to be pathogenic. The tribulation of nonconservative, nonsynonymous, uncommon (<5% incidence) VUS was ~11 per sample. Additional strategies are needed to triage these variants. Third, many individuals in their cohort were affected by one of these diseases. Although a correction was made for compound heterozygote and homozygote alleles, the tribulation assay did not reform for other potential selection biases. Fourth, they did not assess indecent deletions or other copy number variants beyond limited CNV array hybridization and examination of coverage changes in a little number of known deletions. Nevertheless, a tribulation of 2.8 per genome agreed with hypothetical estimates of reproductive lethal allele tribulation (56). It besides concurred with ascetic childhood recessive carrier burdens that they obtained by analyzing published individual genomes [2 substitution disease mutations in the Quake genome and a monozygotic twin pair (21, 57), 5 each in the YH and Watson genomes (58, 59), 4 in the NA07022 genome (60, 61), and 10 in the AK1 genome (20)]. The purview in carrier tribulation was surprisingly narrow (zero to seven per genome). Given the big variations in SNP tribulation and incidence of individual disease alleles among populations, it will be of august interest to evaluate variation in the tribulation of ascetic recessive disease mutations among human populations and how this has been influenced by population bottlenecks.

    Finally, the technology platform described herein is agnostic with regard to target genes or clinical setting. A variety of medical applications for this technology exist beyond exhaust in preconception carrier screening. For example, comprehensive newborn screening for treatable or preventable Mendelian diseases would allow early diagnosis and institution of treatment while neonates are asymptomatic. Early treatment can beget a profound impact on the clinical severity of conditions and could provide a framework for centralized assessment of investigational current treatments before organ failure. In some cases, such as Duarte variant galactosemia, molecular testing would be superior to conventional biochemical testing. Organ or symptom menu-based diagnostic testing, with masking of nonselected conditions, is anticipated to assist clinical geneticists and pediatric neurologists, because current exercise often involves costly, sequential testing of numerous candidate genes. Given impending identification of current disease genes by exome and genome resequencing, the number of disease genes is likely to expand substantially over the next several years, requiring incremental expansion of the target gene sets.

    In summary, a technology platform for comprehensive preconception carrier screening for 448 recessive childhood diseases is described. Combining this technology with genetic counseling could reduce the incidence of ascetic recessive pediatric diseases and may benefit to expedite diagnosis of these disorders in newborns.

    Materials and Methods Disease selection

    Criteria for disease inclusion for preconception screening were broadly based on those for expansion of newborn screening, but with omission of treatment criteria (14). Thus, very broad coverage of ascetic childhood diseases and mutations was sought to maximize cost-benefit, potential reduction in disease incidence, and adoption. A Perl parser identified ascetic childhood recessive disorders with known molecular basis in OMIM (8). Database and literature searches and expert reviews were performed on resultant diseases (8, 27, 28). Six diseases with extreme locus heterogeneity were omitted (OMIM #209900, #209950, Fanconi anemia, #256000, #266510, #214100). Diseases were included if mutations caused ascetic illness in a harmony of affected children and despite variable inheritance, mitochondrial mutations, or low incidence. Mental retardation and mitochondrial genes were excluded. Four hundred and thirty-seven genes, representing 507 recessive diseases, met these criteria, of which 448 diseases were ascetic (table S3).

    DNA samples

    Target enrichment was performed with 104 DNA samples obtained from the Coriell Institute (Camden, NJ) (table S7). Seventy-six of these were known to be carriers or affected by 37 severe, childhood recessive disorders. The latter samples contained 120 known disease mutations in 34 genes (63 substitutions, 20 indels, 13 indecent deletions, 19 splicing, 2 regulatory, and 3 complex disease mutations). They besides represented homozygous, heterozygous, compound heterozygous, and hemizygous disease mutation states. Twenty-six samples were well characterized, from “normal” individuals, and two had previously undergone genome sequencing (21).

    Target enrichment and SBS

    For Illumina GAIIx SBS, 3 μg of DNA was sonicated by Covaris S2 to ~250 nt with 20% duty cycle, 5 intensity, and 200 cycles per burst for 180 s. For Illumina HiSeq SBS, shearing to ~150 nt was by 10% duty cycle, 5 intensity, and 200 cycles per burst for 660 s. Bar-coded sequencing libraries were made per the manufacturer’s protocols. After adaptor ligation, Illumina libraries were prepared with AMPure bead (Beckman Coulter) rather than with gel purification. Library trait was assessed by optical density and electrophoresis (Agilent 2100).

    SureSelect enrichment of 6-, 8-, or 12-plex pooled libraries was per Agilent protocols (15), with 100 ng of custom bait library, blocking oligonucleotides specific for paired-end sequencing libraries and 60-hour hybridization. Biotinylated RNA library hybrids were recovered with streptavidin beads. Enrichment was assessed by quantitative PCR (Life Technologies; CLN3, exon 15, Hs00041388_cn; HPRT1, exon 9, Hs02699975_cn; LYST, exon 5, Hs02929596_cn; PLP1, exon 4, Hs01638246_cn) and a nontargeted locus (chrX: 77082157, Hs05637993_cn) before and after enrichment.

    RainDance RDT1000 target enrichment was as described and used a custom primer library (16, 46): Genomic DNA samples were fragmented by nebulization to 2 to 4 kb and 1 μg mixed with total PCR reagents but primers. Microdroplets containing three primer pairs were fused with PCR reagent droplets and amplified. After emulsion breaking and purification by MinElute column (Qiagen), amplicons were concatenated overnight at 16°C and sequencing libraries were prepared. Sequencing was performed on Illumina GAIIx and HiSeq2000 instruments per the manufacturer’s protocols, as described (20, 21).

    Hybrid capture and SBL

    DNA (3 μg) was sheared by Covaris to ~150 nt with 10% duty cycle, 5 intensity, and 100 cycles per burst for 60 s. Bar-coded fragment sequencing libraries were made with Life Technologies protocols and reagents. Taqman quantitative PCR was used to assess each library, and an equimolar six-plex pool was produced for enrichment with Agilent SureSelect and a modified protocol. Before enrichment, the six-plex pool was single-stranded. Furthermore, 1.2 μg of pooled DNA with 5 μl (100 ng) of custom baits was used for enrichment, with blocking oligonucleotides specific for SOLiD sequencing libraries and 24-hour hybridization. This was the first targeted capture of a multiplex library for SOLiD sequencing, and this protocol has not been subsequently pursued. Alternative methods beget been demonstrated to reduce the pandemonium associated with bar coding and enrichment. Sequencing was performed on a SOLiD 3 instrument with one quadrant on a unique sequencing slide, generating singleton 50-mer reads.

    Sequence analysis

    The bioinformatic conclusion tree for detecting and genotyping disease mutations was predicated on experience with detection and genotyping of variants in next-generation genome and chromosome sequences (20, 21, 33, 34) (Fig. 4). Briefly, SBS sequences were aligned to the National headquarters for Biotechnology Information (NCBI) reference human genome sequence (version 36.3) with GSNAP and scored by rewarding identities (+1) and penalizing mismatches (−1) and indels [−1−log(indel − length)]. Alignments were retained if covering >95% of the read and scoring >78% of maximum. Variants were detected with Alpheus with stringent filters (>14% and >10 reads calling variants and middling trait score >20). Allele frequencies of 14 to 86% were designated heterozygous and >86% homozygous. Reference genotypes of SNPs and CNVs mapping within targets were obtained with Illumina Omni1-Quad arrays and GenomeStudio 2010.1. Indel genotypes were confirmed by genomic PCR of <600-bp flanking variants and Sanger sequencing.

    SBL sequence data analysis was performed with BioScope v1.2. Fifty nucleotide reads were aligned to NCBI genome build 36.3 with a seed and extend approach (max-mapping). A 25-nt seed with up to two mismatches is first aligned to the reference. Extension can proceed in both directions, depending on the footprint of the seed within the read. During extension, each foundation match receives a score of +1, whereas mismatches assemble a default score of −2. The alignment with the highest mapping trait value is chosen as the primary alignment. If two or more alignments beget the identical score, then one of them is randomly chosen as the primary alignment. SNPs were called with the BioScope diBayes algorithm at medium stringency setting (61). diBayes is a Bayesian algorithm that incorporates position and probe errors, as well as color trait value information for SNP calling. Reads with mapping trait of <8 were discarded by diBayes. A position must beget at least 2× or 3× coverage to convoke a homozygous or heterozygous SNP, respectively. The BioScope little indel pipeline was used with default settings and calls insertions of size ≤3 nt and deletions of size ≤11 nt. In comparisons with SBS, SNP and indel calls were further restricted to positions where at least 4 or 10 reads called a variant.

    Indel confirmation

    PCR primers were designed to amplify 100 to 300 nt upstream and downstream of each variant or indel with PrimerQuest (Integrated DNA Technologies). Targeted regions were amplified from 100 ng of genomic DNA, and resultant PCR amplicons were analyzed for predicted size by LCGX (Caliper Life Sciences). Amplicons of preempt size were Sanger-sequenced in both the forward and the reverse directions with the identical primers used for PCR amplification. Analysis was performed with the Mutation Surveyor (SoftGenetics) software package.

    Supplementary Material

    www.sciencetranslationalmedicine.org/cgi/content/full/3/65/65ra4/DC1

    Fig. S1. One finish of five reads from NA01712 showing ERCC6 exon 17, c.3536delA, Y1179fs, chr10:50348476delA.

    Fig. S2. One finish of five reads from NA20383 showing CLN3 exon 11, c.1020G>T, E295X, chr16:28401322G>T (black arrow).

    Fig. S3. One finish of five reads from NA16643 showing HBB exon 2, c.306G>C, E102D, chr11:5204392G>C (black arrow).

    Table S1. Four hundred and forty-eight ascetic pediatric recessive diseases, encompassing 437 genes, that met criteria for carrier screening.

    Table S2. Sequences and genome coordinates of 29,891 Agilent SureSelect 120-mer RNA baits for hybrid capture of 7616 (99.7%) of 7717 segments of 437 genes causing ascetic recessive pediatric disorders.

    Table S3. Custom Agilent SureSelect RNA baits for hybrid capture of 11 indecent deletion DMs with defined boundaries.

    Table S4. reiterate content of 55 exons (5773 nt, 46.27%) failing RNA bait design due to repetitive sequences.

    Table S5. Sequences and genome coordinates of 10,280 primer pairs for microdroplet PCR (RainDance) of 7717 segments of 437 genes causing ascetic recessive pediatric disorders.

    Table S6. Coordinates, genes, and GC content of 40 exons with recurrent coverage <3×.

    Table S7. Confirmed and corrected disease mutations (DMs) in 104 DNA samples, together with enrichment technologies and sequencing platforms used to characterize them.

    Table S8. Variants reported in HGMD to be disease mutations that occurred with incidence >5% in 104 samples by target enrichment and second-generation sequencing or that were assessed to be homozygous in unaffected samples, indicative that they were polymorphisms.

    Table S9. ascetic recessive pediatric disease-causing mutations (DMs) identified in 104 samples by target enrichment and second-generation sequencing.



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/12858175
    Dropmark-Text : http://killexams.dropmark.com/367904/12953569
    Blogspot : http://killexams-braindumps.blogspot.com/2018/01/free-pass4sure-st0-116-question-bank.html
    Wordpress : https://wp.me/p7SJ6L-2RI






    Back to Main Page

    www.pass4surez.com | www.killcerts.com | www.search4exams.com